BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Programmed death ligand 1
1
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift
6/13/2025 1:39:37 PM | Browse: 94 | Download: 511
2
Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma
3/12/2024 10:04:17 AM | Browse: 250 | Download: 731
3
Hepatic arterial infusion chemotherapy with/without anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis
1/26/2024 7:56:29 AM | Browse: 331 | Download: 1270
4
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
7/23/2021 1:30:21 PM | Browse: 697 | Download: 1721
5
Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma
11/12/2020 3:59:23 AM | Browse: 818 | Download: 2253
6
Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer
11/12/2020 3:59:23 AM | Browse: 1020 | Download: 2573
7
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
4/13/2019 6:00:06 AM | Browse: 899 | Download: 1630
8
Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
7/5/2018 1:33:43 AM | Browse: 1007 | Download: 1533
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345